Nevertheless, while MDS harboring dominant TET2 mutant clones seem to have a better response to HMA therapy, MDS with secondary and/or subclonal TET2 mutations tends to exhibit a weaker treatment response. This evidence concerns the gene TET2 and myelodysplastic syndrome.